- Home
- IPSC vs NRSN Comparison
IPSC vs NRSN Comparison
Compare IPSC & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- NRSN
- Stock Information
- Founded
- IPSC 2019
- NRSN 2017
- Country
- IPSC United States
- NRSN Israel
- Employees
- IPSC 165
- NRSN N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- NRSN Health Care
- Exchange
- IPSC Nasdaq
- NRSN Nasdaq
- Market Cap
- IPSC 49.6M
- NRSN 51.1M
- IPO Year
- IPSC 2021
- NRSN 2021
- Fundamental
- Price
- IPSC $0.58
- NRSN $2.35
- Analyst Decision
- IPSC Strong Buy
- NRSN Buy
- Analyst Count
- IPSC 5
- NRSN 2
- Target Price
- IPSC $3.33
- NRSN $14.00
- AVG Volume (30 Days)
- IPSC 868.9K
- NRSN 406.6K
- Earning Date
- IPSC 08-07-2025
- NRSN 07-01-2025
- Dividend Yield
- IPSC N/A
- NRSN N/A
- EPS Growth
- IPSC N/A
- NRSN N/A
- EPS
- IPSC N/A
- NRSN N/A
- Revenue
- IPSC $114,898,000.00
- NRSN N/A
- Revenue This Year
- IPSC $1,064.82
- NRSN N/A
- Revenue Next Year
- IPSC N/A
- NRSN N/A
- P/E Ratio
- IPSC N/A
- NRSN N/A
- Revenue Growth
- IPSC 8286.72
- NRSN N/A
- 52 Week Low
- IPSC $0.34
- NRSN $0.51
- 52 Week High
- IPSC $3.29
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- IPSC 52.16
- NRSN 71.85
- Support Level
- IPSC $0.58
- NRSN $1.90
- Resistance Level
- IPSC $0.66
- NRSN $2.60
- Average True Range (ATR)
- IPSC 0.04
- NRSN 0.21
- MACD
- IPSC -0.00
- NRSN 0.03
- Stochastic Oscillator
- IPSC 41.52
- NRSN 75.49
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.